Stock Trading Canary
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 42.9% (3/7) | 33.3% (1/3) | -3.0% | -3.7% | -15.8% |
| 20D | 2Small sample | 33.3% (2/6) | 0.0% (0/2) | -7.2% | -7.2% | -12.0% |
| 60D | 2Small sample | 33.3% (2/6) | 0.0% (0/2) | -45.4% | -45.4% | -62.2% |
| 120D | 1Small sample | 20.0% (1/5) | 0.0% (0/1) | -57.1% | -57.1% | -57.1% |
COMPANY RESEARCH
Lyell Immunopharma, Inc.
LYEL · United States · Healthcare
Filing summary
Latest qualifying equity purchase · trade date 2026-11-04 · filer ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · published 2026-11-05
Verify source filing ↗ · Held 365-day filing window; a purchase code alone does not establish discretion.
Insider Signal
Snapshot: 06 Nov 2026 · 180-day research window
- Insider Signal
- 71.9 / 100 Research score, not a buy recommendation
- Reported buyers
- 2 180-day scoring window
- Net purchases
- 49.74m USD 180 days · purchases less sales
- Latest disclosure
- 2026-11-05 Publication date
What stands out
- 2 reported buyers participated in qualifying purchases during the last 180 days.
- ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC accounts for 50% of comparable reported purchase value; buyer breadth and value are different measures.
- The share price fell 22.6% over 180 days; inspect disclosure dates before interpreting the purchases.
Price vs insider buying
LYEL · USD● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Where the evidence comes from
The two kinds of evidence disagree: the purchases themselves carry bull lines (large purchases, bought in the last two weeks), while share price and trading argue against (price down over six months). No data is held for: company actions.
- The insider purchases themselvesBulllarge purchases, bought in the last two weeks Bearusual level for this company4 checked, under the threshold · 3 missing
- Share price and tradingBearprice down over six months1 checked, under the threshold
- Short sellers2 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- Net purchases of $49.7M equal 14% of the company's market value ($365.3M): large for the size of the business.
- The latest purchase is 2 days old (2026-11-04). The buying is current, not left over from an earlier quarter.
Bear case · discount it
- Buying at this level is normal here: 2 insiders bought in the previous 180 days and 2 in this one.
- Share price and tradingThe share price is down 23% over six months (three months +3.7%, one month +69%) and stands 67% below its 52-week high. Insiders have bought into a fall the market has not reversed.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin <0.01%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- The 10b5-1 box of these Form 4 filings has not been read, so whether the purchases followed a pre-arranged plan is not known.
- Form 4 states the shares held after each trade. This site reads that from the SEC's quarterly data, which is published after a quarter ends, so it does not have it yet for these filings. Whether a purchase added 1% to a personal stake or doubled it is in the filing, not on this page.
Checked and under the threshold: 8, 2 close to it
- BullAt most 2 insiders bought within any 15 days. Counted for the bull side from 3. close to the threshold
- BearFINRA short interest on 2026-10-15 equals 7.8 days of average trading volume and 5.7% of the 24,505,141 shares outstanding, up 11% from the previous report. Counted for the bear side from 10 days, or from 10% of the shares outstanding. close to the threshold
- BearThe largest buyer accounts for 50% of the value bought. Counted for the bear side from 80%.
- BearInsiders sold $256k in the same 180 days, 0.51% of the amount bought. Counted for the bear side from 25%.
- BearOver three months the share price changed +3.7% and the median of 224 Healthcare companies changed −19%: ahead by 22 points. Counted for the bear side from 20 points behind.
- BearOver the last 5 trading days to 2026-11-06, 48% of this stock's off-exchange volume was sold short; over the 60 days before, 51%. The market's median is 47%. This is trading volume, not a position: a market maker who sells short and covers the same day is counted, so about half of all volume is short on an ordinary day. It is shown for comparison and counts for neither side.
- BearNo insider filing in the last 180 days opened a hedge on this stock.
- BearProfit margin on the latest captured figures is <0.01%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Who is trading?
Named filings in 180 days. Purchase values are summed only when complete and in one currency.
| Insider | Transaction activity | Purchase value | Latest trade | Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLCTenPercentOwner | 1 buy · 0 sell | 25.00m USD | 2026-11-04 | View transactions · 1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTTenPercentOwner | 1 buy · 0 sell | 25.00m USD | 2026-11-04 | View transactions · 1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aguirre Jarrad MattieuExecutive | 0 buy · 1 sell | No purchases | 2026-10-12 | View transactions · 1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bulis Veronica SanchezVP, Corporate Controller | 0 buy · 2 sell | No purchases | 2026-08-10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hill Stephen J.Executive | 0 buy · 3 sell | No purchases | 2026-08-21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Innovative Cellular Therapeutics Holdings LtdTenPercentOwner | 0 buy · 2 sell | No purchases | 2026-07-27 | View transactions · 6
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lee Gary K.Executive | 0 buy · 3 sell | No purchases | 2026-08-21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Seely LynnCEO / chair | 0 buy · 3 sell | No purchases | 2026-08-21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shook DavidExecutive | 0 buy · 2 sell | No purchases | 2026-09-10 |
INSIDER SIGNAL
Score breakdown：71.9 / 100
2 insiders · 2 purchase events · $49.74m net purchases
US #118 · United States #118
WHY THIS SIGNAL?
Score anatomy
Each bar is that part's points in the score; the five parts add up to the score.
Number of buyers+14.0 / 35
How many different insiders bought within 15 days
Amount bought+24.2 / 25
The value bought, net of any insider sales
Buyers' roles+14.0 / 20
Lower in the company scores higher: in the backtest, purchases by the most senior insiders did worse
How recent+9.7 / 10
How long ago the latest purchase took place
Buying against selling+9.9 / 10
Lower when insiders also sold
What is holding the score back?
- ⚠ Few buyers · fewer than 4 different insiders
- ✓ Buyers' roles add a lot · the buyers are below the top of the company
- ✓ Recent buying · latest purchase 2026-11-04
Buyers' roles follow the US order of roles: CEOs, chairs and 10% owners score lowest.
Buying concentration
50%
Largest buyer：ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · 25.00m USD
Purchases counted, before sales：50.00m USD
The amount at the top of the page is purchases minus sales; this one counts purchases only, in the filing currency, so the two can differ. The score counts how many people bought; this shows separately who bought the most.
This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC | 10.77 USD | Nov 4, 2026 |
| ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | 10.77 USD | Nov 4, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 2 distinct reported filers
- Peak time window
- 2026-11-04 to 2026-11-04
- Current breadth input
- 0.400 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Latest purchase counted
ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · 25.00m USD · Price 10.77 USD · Nov 4, 2026 - 🟢 Purchase counted
ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · 25.00m USD · Price 10.77 USD · Nov 4, 2026 - 🔴 20 other line(s) are not counted, as they are not purchases the insider chose to make; 4 have a price of zero
Filing and data quality
These checks are auditable context; they do not change the rank or score.
- Identity match
- REVIEW
- Ticker / ISIN
- Ticker or ISIN missing
- Filing source links
- 41 / 41
- Median disclosure lag
- 2 days
- Latest disclosure age
- 1 days at snapshot
- Corrections / revisions
- 0
- Score-factor detail
- Saved
Insider timeline
2 insiders bought on the same day, 4 Nov: 2 Associated person. The share closed at 15.43 that day and at 14.86 most recently (−3.7%). That week 87 companies across United States disclosed insider purchases, an ordinary week (19 of the last 26).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
▮Purple band: several insiders bought within 15 days
The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 4 Nov, with 2 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.
Blue line: this share's price, −22.6% over these six months
The closing price of each day, from 19.20 on 2026-05-11 to 14.86 on 2026-11-06. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −9.6%
Taken from the 1644 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −22.6%, the typical one −9.6%, 13.0 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across United States disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 87 companies, number 19 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.
This company: insiders buying per month, last 12 months
Dec
Jan
Feb
2Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
2Nov
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| Hill Stephen J. | Executive | — | 3 | — | — | — |
| Lee Gary K. | Executive | — | 3 | — | — | — |
| Seely Lynn | CEO / chair | — | 3 | — | — | — |
| Shook David | Executive | — | 2 | — | — | — |
| Aguirre Jarrad Mattieu | Executive | — | 1 | — | — | — |
| Bulis Veronica Sanchez | Role not classified | — | 2 | — | — | — |
| Innovative Cellular Therapeutics Holdings Ltd | Associated person | — | 2 | — | — | — |
| ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC | Associated person | 1 | — | 25.0M USD | 2026-11-04 | −3.7% |
| ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | Associated person | 1 | — | 25.0M USD | 2026-11-04 | −3.7% |
Purchases against sales
Purchases99%50.0M USD · 2 line(s) · 2 insider(s)
Sales1%255.5k USD · 16 line(s) · 7 insider(s)
Shares of the reported value of insider transactions in the 180-day window. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.
Insiders' buying price vs the latest close
Insiders paid 13.35 USD a share on average (4 purchase lines, 2 buyers, 2026-03-06 – 2026-11-04). The close on 2026-11-06 was 11.3% above that price.
The latest purchase (2026-11-04) was at 10.77 USD; the close was 38.0% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Buying size vs market trading
Complete price and volume history is not yet available.
Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Sector context
- Buying breadth
- 4.7% (48 / 1,020 issuers)
- Sector rank
- #7 / 13
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − S&P 500 ETF (SPY adjusted close) return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 42.9% (3/7) | 33.3% (1/3) | -3.0% | -3.7% | -15.8% |
| 20D | 2Small sample | 33.3% (2/6) | 0.0% (0/2) | -7.2% | -7.2% | -12.0% |
| 60D | 2Small sample | 33.3% (2/6) | 0.0% (0/2) | -45.4% | -45.4% | -62.2% |
| 120D | 1Small sample | 20.0% (1/5) | 0.0% (0/1) | -57.1% | -57.1% | -57.1% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 42.9% (3/7) | 33.3% (1/3) | -3.0% | -3.7% | -15.8% |
| 20D | 2Small sample | 33.3% (2/6) | 0.0% (0/2) | -7.2% | -7.2% | -12.0% |
| 60D | 2Small sample | 33.3% (2/6) | 0.0% (0/2) | -45.4% | -45.4% | -62.2% |
| 120D | 1Small sample | 20.0% (1/5) | 0.0% (0/1) | -57.1% | -57.1% | -57.1% |
Signal outcomes
Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.
| Horizon | Status | Result |
|---|---|---|
| 5D | Awaiting maturity | — |
| 20D | Awaiting maturity | — |
| 60D | Awaiting maturity | — |
| 120D | Awaiting maturity | — |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 99.9%
- Beta
- -0.09
- Avg daily volume
- $2.4M
- 20-session drawdown
- -9.2%
- 60-session drawdown
- -52.4%
- Latest volume / prior median
- 1.8×
VALUATION
- Market cap
- $365.3M
- Market cap (EUR ref.)
- $327.2M
- P/E
- —
FUNDAMENTALS
- Revenue
- $36,000.0
- Net income
- $-274.4M
- Operating profit
- $-269.4M
- Equity
- $248.2M
- Cash
- $61.8M
- Debt
- —
- Operating cash flow
- $-150.0M
- Free cash flow
- $-150.8M
- Profit margin
- 0.0%
- ROE
- -93.3%
- Industry
- Biotechnology
Prices to 07 Nov 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 07 Nov 2026: Market cap, Revenue, Net income, Equity, Operating profit, Cash, Operating cash flow, Free cash flow, Profit margin, ROE, Beta, Industry. ECB EUR reference rate dated 2026-11-06; it is not a trade-date conversion. It does not affect the insider score or rank.
Dividends
No cash dividend in the last five years.
Yahoo Finance: cash dividends by ex-dividend date, the latest close, the payout ratio (dividends ÷ 12-month earnings per share) and announced dates; special dividends included, stock dividends and splits not. Not part of any score.
Insiders and institutions
Insiders, ranking window: $49.7M net bought · buyers: 2 · last 2026-11-04
Holders of more than 5% (SEC Schedules 13D and 13G)
| Holder | Of the class | Schedule | As of | Change |
|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13.90% | 13G | 2026-03-31 | +0.90 pp |
| Innovative Cellular Therapeutics Holdings Limited | 12.30% | 13G | 2026-05-18 | +2.50 pp |
| EULER FUND, L.P. | 6.71% | 13G | 2026-03-06 | — |
| Explore Investments LLC | 6.60% | 13G | 2026-03-31 | +1.20 pp |
| Gates Frontier, LLC | 5.60% | 13G | 2025-07-25 · over a year ago | — |
Filings in the last 12 months
1 new · 3 raised · 0 cut · 2 fell to 5% or less
| As of | Holder | Schedule | Stake | What happened |
|---|---|---|---|---|
| 2026-06-30 | James B. Tananbaum | 13G | 7.60% → 2.70% | 5% or less |
| 2026-05-18 | Innovative Cellular Therapeutics Holdings Limited | 13G | 9.80% → 12.30% | raised |
| 2026-03-31 | MWG Caph Ltd | 13G | — → 4.30% | 5% or less |
| 2026-03-31 | Explore Investments LLC | 13G | 5.40% → 6.60% | raised |
| 2026-03-31 | ARCH Venture Fund IX, L.P. | 13G | 13.00% → 13.90% | raised |
| 2026-03-06 | EULER FUND, L.P. | 13G | — → 6.71% | new holding |
Source: SEC, Schedules 13D and 13G, filed in a structured format since 18 December 2024; earlier filings are not read, so a holder that has not filed since then is not shown. 13D: the holder may seek to influence the company (activists, founders, strategic holders); it must amend within two business days of a change of 1% or more. 13G: the holder states it holds passively; it amends within 45 days after the quarter in which its holding changed materially, so a figure can be months old. The percentage is the filer's own, of the class of shares it names. Context only; not part of the score.
Institutional managers (SEC Form 13F)
- Held on 2026-06-30
- $166.1M86 managers · 12.0M shares · 48.9% of the shares outstanding (SEC cover page, 2026-08-03)
- Shares held, change on the quarter
- +0.1%since 2026-03-31
- Change on the year
- +75.7%since 2025-06-30
- Managers
- 23 new · 28 added · 19 cut · 10 sold out
The shares 13F managers held changed little on the quarter.
Source: SEC Form 13F, filed within 45 days of each quarter end by managers with $100 million or more in US-listed shares; long positions only (no short positions, options left out). Late filers of the quarter are not counted. A parent and a subsidiary can both report the same shares, so the total can count some twice. The quarter end (2026-06-30) and the insiders' purchases (last 2026-11-04) are different periods. Context only; not part of the score.
Regulatory filings
- Insider filing announcement · published 2026-11-05 · trade date 2026-11-04
- Insider filing announcement · published 2026-11-05 · trade date 2026-11-04
- Insider filing announcement · published 2026-10-13 · trade date 2026-10-12
Unfold all 36 filings
- Insider filing announcement · published 2026-11-05 · trade date 2026-11-04
- Insider filing announcement · published 2026-11-05 · trade date 2026-11-04
- Insider filing announcement · published 2026-10-13 · trade date 2026-10-12
- Insider filing announcement · published 2026-09-10 · trade date 2026-09-10
- Insider filing announcement · published 2026-08-25 · trade date 2026-08-21
- Insider filing announcement · published 2026-08-25 · trade date 2026-08-21
- Insider filing announcement · published 2026-08-25 · trade date 2026-08-21
- Insider filing announcement · published 2026-08-11 · trade date 2026-08-10
- Insider filing announcement · published 2026-08-11 · trade date 2026-08-10
- Insider filing announcement · published 2026-08-11 · trade date 2026-08-10
- Insider filing announcement · published 2026-08-11 · trade date 2026-08-10
- Insider filing announcement · published 2026-07-27 · trade date 2026-07-27
- Insider filing announcement · published 2026-07-27 · trade date 2026-07-27
- Insider filing announcement · published 2026-07-20 · trade date 2026-07-17
- Insider filing announcement · published 2026-07-17 · trade date 2026-07-16
- Insider filing announcement · published 2026-07-01 · trade date 2026-06-29
- Insider filing announcement · published 2026-06-18 · trade date 2026-06-15
- Insider filing announcement · published 2026-06-15 · trade date 2026-05-11
- Insider filing announcement · published 2026-06-15 · trade date 2026-05-11
- Insider filing announcement · published 2026-06-15 · trade date 2026-05-11
- Insider filing announcement · published 2026-06-15 · trade date 2026-05-11
- Insider filing announcement · published 2026-06-11 · trade date 2026-06-10
- Insider filing announcement · published 2026-03-09 · trade date 2026-03-06
- Insider filing announcement · published 2026-03-09 · trade date 2026-03-06
- Insider filing announcement · published 2026-02-12 · trade date 2026-02-11
- Insider filing announcement · published 2026-02-12 · trade date 2026-02-11
- Insider filing announcement · published 2026-02-12 · trade date 2026-02-11
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-10
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-10
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-10
- Insider filing announcement · published 2026-02-11 · trade date 2026-02-10
- Insider filing announcement · published 2026-01-06 · trade date 2025-12-30
- Insider filing announcement · published 2025-11-12 · trade date 2025-11-10
- Insider filing announcement · published 2025-11-12 · trade date 2025-11-10
- Insider filing announcement · published 2025-11-12 · trade date 2025-11-10
- Insider filing announcement · published 2025-11-12 · trade date 2025-11-10
Results and insider purchases
| Results (8-K) | Bought within 5 sessions | Bought within 20 sessions | Buyers, 20 sessions before |
|---|---|---|---|
| 2026-11-0416:14 ET · after the closeFirst session 2026-11-05 | None1/5 sessions so far | None1/20 sessions so far | 14 |
| 2026-08-0616:14 ET · after the closeFirst session 2026-08-07 | None | None | 0 |
| 2026-05-0616:10 ET · after the closeFirst session 2026-05-07 | None | None | 0 |
| 2026-03-1216:12 ET · after the closeFirst session 2026-03-13 | None | None | 14 |
Results dates are the company's 8-K filings to the SEC under Item 2.02 (results of operations); one filed after the close counts from the next session. Purchases are open-market buys reported on Form 4 (code P), by trade date; a Form 4 can arrive two business days after the trade, so the latest days can still fill in. Facts only; this does not change the score or rank.
Ownership and trading-plan context
| Direct / indirect ownership | Direct, Indirect |
|---|---|
| 10b5-1 filing evidence | Not declared in filing field |
| Evidence retrieved | 2026-11-06T23:58:05+00:00 |
These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
4 qualifying purchase disclosure(s) · 4 transaction line(s)
Trade Mar 6, 2026Open market purchase
ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · TenPercentOwner
Published Mar 9, 2026 · Common Stock · 488090.0 shares × 25.61 USD · 12499984.9 USD
Open filingTrade Mar 6, 2026Open market purchase
ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · TenPercentOwner
Published Mar 9, 2026 · Common Stock · 488090.0 shares × 25.61 USD · 12499984.9 USD
Open filingTrade Nov 4, 2026Open market purchase
ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · TenPercentOwner
Published Nov 5, 2026 · Common Stock · 2321262 shares × 10.77 USD · 24999991.74 USD
Open filingUnfold all 1 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-04 | 2026-11-05 | ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT | TenPercentOwner | Open market purchase | Common Stock | 10.77 USD | USD | 2321262 | 24999991.74 USD | Open filing |
Showing 4 of 4 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 37 other transaction(s)
Trade Nov 10, 2025Open market sale
Seely Lynn · President and CEO
Published Nov 12, 2025 · Common Stock · 412.0 shares × 16.11 USD · 6637.32 USD
Open filingTrade Nov 10, 2025Open market sale
Bulis Veronica Sanchez · VP, Corporate Controller
Published Nov 12, 2025 · Common Stock · 239.0 shares × 16.1 USD · 3847.9000000000005 USD
Open filingTrade Nov 10, 2025Open market sale
Lee Gary K. · Chief Scientific Officer
Published Nov 12, 2025 · Common Stock · 138.0 shares × 16.16 USD · 2230.08 USD
Open filingUnfold all 34 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-10 | 2025-11-12 | Hill Stephen J. | Chief Operating Officer | Open market sale | Common Stock | 16.12 USD | USD | 95.0 | 1531.4 USD | Open filing |
| 2026-02-11 | 2026-02-12 | Seely Lynn | President and CEO | Open market sale | Common Stock | 23.39 USD | USD | 7455.0 | 174372.45 USD | Open filing |
| 2026-02-11 | 2026-02-12 | Hill Stephen J. | Chief Operating Officer | Open market sale | Common Stock | 23.39 USD | USD | 1236.0 | 28910.04 USD | Open filing |
| 2026-02-11 | 2026-02-12 | Lee Gary K. | Chief Scientific Officer | Open market sale | Common Stock | 23.39 USD | USD | 1671.0 | 39084.69 USD | Open filing |
| 2026-02-10 | 2026-02-11 | Hill Stephen J. | Chief Operating Officer | Open market sale | Common Stock | 23.12 USD | USD | 109.0 | 2520.08 USD | Open filing |
| 2026-02-10 | 2026-02-11 | Lee Gary K. | Chief Scientific Officer | Open market sale | Common Stock | 23.12 USD | USD | 147.0 | 3398.6400000000003 USD | Open filing |
| 2026-02-10 | 2026-02-11 | Seely Lynn | President and CEO | Open market sale | Common Stock | 23.12 USD | USD | 438.0 | 10126.560000000001 USD | Open filing |
| 2026-02-10 | 2026-02-11 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | Common Stock | 23.12 USD | USD | 254.0 | 5872.4800000000005 USD | Open filing |
| 2026-02-10 | 2026-02-11 | Bulis Veronica Sanchez | VP, Corporate Controller | Grant or award | Common Stock | 0.0 USD | USD | 8750.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Hill Stephen J. | Chief Operating Officer | Grant or award | Common Stock | 0.0 USD | USD | 4000.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Lee Gary K. | Chief Scientific Officer | Grant or award | Common Stock | 0.0 USD | USD | 4000.0 | 0.0 USD | Open filing |
| 2026-02-09 | 2026-02-11 | Seely Lynn | President and CEO | Grant or award | Common Stock | 0.0 USD | USD | 20000.0 | 0.0 USD | Open filing |
| 2025-12-30 | 2026-01-06 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | Common Stock | 32.32 USD | USD | 936.0 | 30251.52 USD | Open filing |
| 2025-12-24 | 2026-01-06 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | Common Stock | 38.67 USD | USD | 1136.0 | 43929.12 USD | Open filing |
| 2026-06-15 | 2026-06-18 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Other acquisition or disposition | Common Stock | 0.0 USD | USD | 66500.0 | 0.0 USD | Open filing |
| 2026-06-10 | 2026-06-11 | Shook David | Chief Medical Officer | Open market sale | Common Stock | 12.64 USD | USD | 1977.0 | 24989.280000000002 USD | Open filing |
| 2026-05-11 | 2026-06-15 | Seely Lynn | President and CEO | Open market sale | Common Stock | 18.91 USD | USD | 388.0 | 7337.08 USD | Open filing |
| 2026-05-11 | 2026-06-15 | Lee Gary K. | Chief Scientific Officer | Open market sale | Common Stock | 18.92 USD | USD | 130.0 | 2459.6000000000004 USD | Open filing |
| 2026-05-11 | 2026-06-15 | Hill Stephen J. | Chief Operating Officer | Open market sale | Common Stock | 18.92 USD | USD | 89.0 | 1683.88 USD | Open filing |
| 2026-05-11 | 2026-06-15 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | Common Stock | 18.91 USD | USD | 217.0 | 4103.47 USD | Open filing |
| 2026-09-10 | 2026-09-10 | Shook David | Chief Medical Officer | Open market sale | Common Stock | 12.7 USD | USD | 500.0 | 6350.0 USD | Open filing |
| 2026-08-21 | 2026-08-25 | Seely Lynn | President and CEO | Open market sale | Common Stock | 15.54 USD | USD | 9589.0 | 149013.06 USD | Open filing |
| 2026-08-21 | 2026-08-25 | Hill Stephen J. | Chief Operating Officer | Open market sale | Common Stock | 15.54 USD | USD | 989.0 | 15369.06 USD | Open filing |
| 2026-08-21 | 2026-08-25 | Lee Gary K. | Chief Scientific Officer | Open market sale | Common Stock | 15.54 USD | USD | 1457.0 | 22641.78 USD | Open filing |
| 2026-08-10 | 2026-08-11 | Bulis Veronica Sanchez | VP, Corporate Controller | Open market sale | Common Stock | 14.34 USD | USD | 621.0 | 8905.14 USD | Open filing |
| 2026-08-10 | 2026-08-11 | Lee Gary K. | Chief Scientific Officer | Open market sale | Common Stock | 14.34 USD | USD | 131.0 | 1878.54 USD | Open filing |
| 2026-08-10 | 2026-08-11 | Hill Stephen J. | Chief Operating Officer | Open market sale | Common Stock | 14.34 USD | USD | 89.0 | 1276.26 USD | Open filing |
| 2026-08-10 | 2026-08-11 | Seely Lynn | President and CEO | Open market sale | Common Stock | 14.34 USD | USD | 390.0 | 5592.6 USD | Open filing |
| 2026-07-27 | 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Other acquisition or disposition | Common Stock | 0.0 USD | USD | 44000.0 | 0.0 USD | Open filing |
| 2026-07-27 | 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Other acquisition or disposition | Common Stock | 0.0 USD | USD | 38500.0 | 0.0 USD | Open filing |
| 2026-07-17 | 2026-07-20 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Open market sale | Common Stock | 13.7 USD | USD | 10.0 | 137.0 USD | Open filing |
| 2026-07-16 | 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Open market sale | Common Stock | 13.73 USD | USD | 10.0 | 137.3 USD | Open filing |
| 2026-06-29 | 2026-07-01 | Innovative Cellular Therapeutics Holdings Ltd | TenPercentOwner | Other acquisition or disposition | Common Stock | 0.0 USD | USD | 76000.0 | 0.0 USD | Open filing |
| 2026-10-12 | 2026-10-13 | Aguirre Jarrad Mattieu | Chief Medical Officer | Open market sale | Common Stock | 8.63 USD | USD | 422 | 3641.86 USD | Open filing |
Showing 37 of 37 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Follow new disclosures
Subscribe to new United States disclosures. These are market-wide RSS feeds, not company-specific alerts.
Model & Sources
Signal history
71.9 / 100
Latest recorded score
→ +0.0 ptssince the first recorded snapshot on 2026-11-06; 0 calendar days observed
- Recorded snapshots
- 1
- First snapshot
- 2026-11-06
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 71.9
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-11-06 | 71.9 |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.400 | 14.0 |
| Qualified-buy size | 25% | 0.970 | 24.2 |
| Role informativeness (inverted) | 20% | 0.700 | 14.0 |
| Recency | 10% | 0.967 | 9.7 |
| Buy/sell conviction | 10% | 0.995 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
Snapshot & identity
- Snapshot date
- 2026-11-06
- Ticker
- LYEL
- ISIN
- —
- Sector
- Healthcare
- Industry
- —
Company logos by Parqet
How to read Form 4 transaction codes
| Code | Interpretation | Screen treatment |
|---|---|---|
| P | Open-market / private purchase | Buy evidence when the security is qualifying equity |
| S | Sale | Sell evidence when the security is qualifying equity |
| A | Grant / award | Context only |
| F | Tax-related withholding | Context only |
| M | Option exercise | Context only |
| G | Gift | Context only |
| J / L | Other / non-directional | Context only |
P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.